- Alnylam reported Q3 2026 net product revenues of $1.29 billion (52% YoY growth).
- Alnylam Pharmaceuticals (ALNY) resumes trading after earnings halt.
Trading in ALNY has resumed after a halt earlier today. The halt coincided with the company's Q3 earnings release, which showed strong revenue growth and reaffirmed guidance.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.